Yes, a fading sense of smell can be an early warning sign of Alzheimer’s disease and should trigger attention from both individuals and their healthcare providers. Research over the past two decades has consistently shown that olfactory dysfunction—the loss or distortion of smell—often precedes cognitive decline by years, making it one of the earliest detectable biomarkers of neurodegeneration. A person who once noticed the aroma of their morning coffee but suddenly finds it has no scent, or who can no longer distinguish between the smell of their spouse’s perfume and an unfamiliar fragrance, may be experiencing more than a sinus problem or age-related decline; they may be showing one of the first signs that Alzheimer’s pathology is affecting their brain. The connection between smell and Alzheimer’s exists because the olfactory system is directly connected to the limbic system and the entorhinal cortex—brain regions where amyloid plaques and tau tangles, the pathological hallmarks of Alzheimer’s, first accumulate. Unlike other senses, the olfactory nerve provides nearly direct access to deep brain structures involved in memory and emotion.
When these regions degenerate, the ability to detect and process odors deteriorates. For many people with early-stage Alzheimer’s, smell loss occurs without other noticeable symptoms; they maintain normal cognition on standard tests and show no memory problems that worry their families. The challenge is that smell loss alone is ambiguous. It can result from nasal polyps, chronic sinusitis, COVID-19 aftereffects, nutritional deficiencies, or medications—all conditions that have nothing to do with dementia. This ambiguity means that smell loss requires investigation rather than panic, but it also means that when smell loss appears alongside other subtle changes, it should not be dismissed as a normal part of aging.
Table of Contents
- How Does Olfactory Dysfunction Connect to Alzheimer’s Pathology?
- What Types of Smell Loss Occur in Alzheimer’s Disease?
- Why Is Olfactory Testing Important for Early Detection?
- What Should You Do If You Notice Worsening Smell or Taste?
- What Are the Limitations and Challenges of Using Smell Loss as a Diagnostic Marker?
- How Does Smell Loss Affect Quality of Life in Dementia?
- When Should Smell Loss Prompt Genetic or Biomarker Testing?
- Frequently Asked Questions
How Does Olfactory Dysfunction Connect to Alzheimer’s Pathology?
The olfactory bulb, a small grape-sized structure at the base of the brain, receives signals directly from smell receptors in the nasal cavity. This unique anatomical position means the olfactory system is exposed to the external environment in ways other sensory systems are not, and it sits at the gateway to regions critical for memory. Researchers have found that amyloid-beta and tau—the proteins that form the toxic plaques and tangles associated with Alzheimer’s—accumulate in the olfactory bulb and entorhinal cortex before they spread to wider areas of the cortex. In studies of postmortem brain tissue from Alzheimer’s patients, the olfactory bulb often shows severe pathological changes even when other brain regions show minimal degeneration. This early accumulation of Alzheimer’s pathology in the olfactory system explains why smell loss can appear years before memory loss or confusion becomes noticeable.
A 72-year-old man might report to his doctor that he can no longer enjoy the smell of his garden, his morning coffee tastes bland, and cooking odors that once filled his kitchen now register as almost nothing—while his cognitive testing and memory remain normal. Yet if this same person’s brain were scanned with advanced neuroimaging or examined postmortem, that olfactory bulb would likely show the same neuropathological signature as a patient with moderate dementia. The disconnect between the absence of smell and the presence of cognitive symptoms creates a diagnostic window that is difficult to act upon. Animal studies have provided more direct evidence of this relationship. Mice genetically engineered to develop Alzheimer’s-like pathology show loss of smell receptors and olfactory bulb degeneration before developing cognitive deficits, demonstrating that the sequence is not coincidental but causal. Human studies using PET imaging and cerebrospinal fluid biomarkers have shown that people with reduced sense of smell have higher levels of amyloid-beta and phosphorylated tau in their brains, even when they show no signs of cognitive impairment.
What Types of Smell Loss Occur in Alzheimer’s Disease?
Olfactory dysfunction in Alzheimer’s takes several distinct forms, and understanding which type a person experiences can offer clues about disease progression. Some people lose their ability to detect odors altogether—a condition called hyposmia when the sense is diminished and anosmia when it is absent. Other people retain the ability to perceive that something smells, but cannot identify what it is; they might smell something pungent but cannot recognize whether it is coffee, perfume, or a spoiled food. This loss of odor identification without loss of odor detection is particularly common in early Alzheimer’s and may be among the first olfactory changes to appear. A third type, parosmia, involves the distortion or misidentification of smells. A person might smell their favorite meal cooking and perceive it as revolting, or encounter an odor they used to enjoy and find it unpleasant or unrecognizable.
This is distinct from the normal age-related decline in smell sensitivity, which typically affects the intensity of perception—older adults may simply perceive odors as fainter. In Alzheimer’s, the deficit is more often qualitative; the person’s brain cannot properly process or interpret the odor signal, even if the signal reaches the olfactory bulb. The specific pattern matters because odor identification loss appears to correlate more strongly with cognitive decline than odor detection loss alone. Researchers have developed standardized tests—the Smell Identification Test being one of the most common—that present a person with scratch-and-sniff odors and ask them to identify which of four options the smell matches. People in the early stages of Alzheimer’s disease often perform poorly on identification tests even when their pure detection thresholds remain relatively intact. A limitation of relying on smell tests alone is that performance can be influenced by education, prior olfactory experience, and cultural familiarity with the odors used; the same test might yield different results for someone who grew up in an arid climate versus a tropical one.
Why Is Olfactory Testing Important for Early Detection?
The value of smell testing lies in its potential to identify Alzheimer’s pathology before cognitive symptoms appear—a period researchers call preclinical Alzheimer’s disease. During this stage, a person may be accumulating brain amyloid and tau for years without any noticeable memory problems or cognitive changes. A standardized smell identification test could serve as an inexpensive, non-invasive screening tool to identify people at higher risk for future cognitive decline. In a large prospective study published over a decade ago, researchers followed people without dementia and found that those with the worst smell identification scores were significantly more likely to develop cognitive impairment over the next five years. One practical application is in routine memory or geriatric clinics. A primary care doctor might include a simple smell test as part of the cognitive screening for an older patient, much as they now check blood pressure or cholesterol.
If the test reveals poor smell identification, it could prompt further evaluation—cognitive testing, neuropsychological assessment, or biomarker testing—before the person has developed symptoms noticeable enough to bring them to a specialist. Early identification is valuable because it allows for earlier initiation of disease-modifying treatments, if available, and gives individuals and families time to plan for potential cognitive changes. However, there are important limitations to this approach. Smell loss is not specific to Alzheimer’s; many conditions cause it, and many people with poor smell function never develop dementia. Additionally, smell identification tests are not standardized across all clinical settings, and they are not yet widely used as a routine screening tool. The tests can be affected by nasal congestion, recent viral infection, or even a person’s mood and attention level on the day of testing. Without clear clinical guidelines on how to interpret and act upon a poor smell test in an asymptomatic person, the test’s clinical utility remains uncertain.
What Should You Do If You Notice Worsening Smell or Taste?
The first step is not to assume that smell loss is a sign of dementia. If someone notices a sudden or gradual loss of smell, the appropriate response is to see a primary care physician or an otolaryngologist (ear, nose, and throat specialist) to rule out reversible causes. Chronic rhinosinusitis, nasal polyps, seasonal allergies, and upper respiratory infections can all cause temporary or persistent loss of smell and are often treatable. A medication review is also important; many drugs—including certain blood pressure medications, cholesterol-lowering agents, and antihistamines—can affect smell and taste. If a medication is the culprit, switching to an alternative often restores the sense of smell.
Once reversible medical causes have been addressed or ruled out, the conversation should shift to brain health evaluation. A person with unexplained smell loss might benefit from cognitive screening, a discussion with their primary care doctor about their personal and family history of dementia, and potentially referral to a memory specialist or neurologist. Advanced brain imaging or cerebrospinal fluid biomarker testing (which requires a lumbar puncture) can assess whether Alzheimer’s pathology is present, though these tests are typically reserved for research settings or specialized memory clinics rather than routine care. A comparison is useful here: the presence of smell loss is somewhat like the presence of a warning light on a car’s dashboard—it indicates that something warrants investigation, but the light itself does not identify the specific problem. For someone already diagnosed with mild cognitive impairment or early-stage Alzheimer’s, smell testing may offer a baseline marker for tracking disease progression. Some research suggests that olfactory dysfunction worsens as Alzheimer’s advances, and future studies may reveal that serial smell testing could serve as a low-cost way to monitor disease trajectory alongside more complex neuropsychological testing.
What Are the Limitations and Challenges of Using Smell Loss as a Diagnostic Marker?
While the link between smell loss and Alzheimer’s is scientifically robust, translating this research finding into clinical practice faces several obstacles. First, smell loss is common in older adults for many reasons unrelated to dementia—smoking history, occupational exposures, and age itself all reduce olfactory function. In one population-based study, nearly 25% of older adults without cognitive impairment had significantly impaired smell, which would lead to an unacceptable rate of false positives if smell testing alone were used as a screening tool. The specificity of smell loss for Alzheimer’s is moderate at best. Second, the lack of standardized testing across clinical settings creates inconsistency. Some clinics use the University of Pennsylvania Smell Identification Test (UPSIT), while others use the Brief Smell Identification Test or the Odor Identification Test.
Each test contains different odors, uses different methodology, and may yield different results for the same person. Without standardization, it is difficult to compare results across different medical encounters or to establish clear thresholds for what constitutes “impaired” smell. A third challenge is that smell loss can have onset and progression independent of cognitive decline. A person might have poor smell identification at age 70 but remain cognitively normal for the next 20 years, while another person with normal smell function might develop Alzheimer’s in their early 80s. Smell loss is probabilistically associated with higher dementia risk, but it is not deterministic; it does not predict whether a specific individual will develop cognitive decline. This uncertainty creates an ethical dilemma in clinical practice: what does a physician tell a 73-year-old with newly recognized smell loss and no cognitive symptoms? The information is statistically meaningful but individually unclear.
How Does Smell Loss Affect Quality of Life in Dementia?
Beyond its role as a biomarker, olfactory dysfunction significantly impacts the lived experience of people with Alzheimer’s disease. Smell is intimately connected to taste—the flavor of food depends heavily on olfactory input from the back of the nose—so people with smell loss often experience foods as bland or unpalatable. This can lead to poor appetite, inadequate nutrition, and weight loss. An 81-year-old woman with early Alzheimer’s might report that her favorite pasta dish, once something she looked forward to eating, now has almost no flavor. She eats less, becomes malnourished, and her overall health and energy decline.
Smell also serves emotional and social functions. The scent of a loved one, a familiar perfume, or a favorite place carries emotional weight and can trigger memories and feelings of connection. When these olfactory connections fade, people with dementia may feel a loss of continuity with their past and a reduced sense of engagement with their environment. Some family members report that a loved one with Alzheimer’s no longer responds to familiar scents in ways they once did—they don’t smile at the smell of baking, don’t recognize the scent of their spouse, don’t react to the smell of their childhood home. This loss of olfactory-mediated emotion is real and contributes to the broader sense of disconnection that accompanies cognitive decline.
When Should Smell Loss Prompt Genetic or Biomarker Testing?
Not every instance of smell loss warrants genetic testing or advanced biomarker evaluation, but the combination of smell loss with other risk factors or symptoms warrants consideration. Someone with smell loss who also has a first-degree relative with Alzheimer’s disease, or who has a documented genetic risk variant (such as the APOE4 allele), might benefit from more aggressive screening. Similarly, a person with smell loss who develops subtle memory changes, difficulty with complex tasks, or mood changes should be evaluated by a memory specialist.
Advanced biomarker testing—including blood tests for phosphorylated tau and amyloid-beta, PET imaging, or MRI—can provide more definitive information about whether Alzheimer’s pathology is present. These tests are increasingly available in specialized memory clinics and are becoming part of the routine workup for cognitive concerns. A practical tradeoff exists between the value of early detection and the cost, accessibility, and potential psychological burden of biomarker testing. For some individuals, knowing their biomarker status empowers them to plan their future and engage with preventive strategies; for others, the knowledge of asymptomatic pathology creates anxiety without changing management.
Frequently Asked Questions
Can smell loss from a cold or allergy be confused with Alzheimer’s-related smell loss?
Yes. Temporary smell loss from a viral infection, sinus infection, or allergies can be reversed once the underlying condition clears. Alzheimer’s-related smell loss is typically progressive and persistent. If smell loss lasts longer than a few weeks after a cold resolves, or if it continues despite treating allergies or sinusitis, it warrants further evaluation.
Is smell loss a certain sign that someone will develop Alzheimer’s dementia?
No. Smell loss increases the statistical risk of future cognitive decline, but many people with impaired smell function never develop dementia. Conversely, some people with normal smell function do develop Alzheimer’s. Smell loss is one risk factor among many.
Are smell identification tests available in a regular doctor’s office?
Most general practice settings do not routinely perform smell testing. Some memory clinics, geriatric practices, and ENT offices offer standardized smell tests, but they are not yet part of standard primary care screening. Ask your doctor if they offer smell testing or can refer you to a clinic that does.
Can treating smell loss prevent or slow Alzheimer’s disease?
Currently, no treatment directly restores smell function in people with Alzheimer’s disease. However, addressing reversible causes of smell loss (such as nutritional deficiencies, medication side effects, or sinus disease) may improve olfactory function and overall quality of life.
What is the difference between smell and taste?
Taste (gustation) involves the taste buds on the tongue and detects sweet, salty, bitter, sour, and savory. Smell (olfaction) involves receptors in the nasal cavity. The perception of “flavor” is mostly smell; when you lose smell, food tastes bland because the olfactory component of flavor perception is absent.
Should someone with newly discovered smell loss be worried about having Alzheimer’s?
Smell loss should prompt investigation—a doctor’s visit, evaluation for reversible causes, and possibly cognitive screening—but not panic. Most causes of smell loss are not Alzheimer’s-related. However, if smell loss is accompanied by other changes in cognition, mood, or function, medical evaluation should be more thorough.
